Category Archives: investing

Vapen MJ Ventures Announces Listing on Frankfurt Stock Exchange

Vapen MJ Ventures Announces Listing on Frankfurt Stock Exchange

Vapen MJ Ventures (CSE: VAPN) (“Vapen MJ”) a fully integrated agricultural technology, services and property management company in the regulated cannabis industry, today announced that its common shares are now listed on the Frankfurt Stock Exchange (FSE) trading under the ticker symbol “VV5”. The Company continues to be listed on the Canadian Securities Exchange (CSE) under the ticker symbol “VAPN”.

Bob Brilon, president and chief financial officer of Vapen MJ Ventures, commented, “Listing the common shares of Vapen MJ Ventures on the Frankfurt Exchange is another important step in our evolution, helping increase awareness of our progress with the global investor community. The cannabis markets continue to expand around the world, and Vapen MJ is increasingly well-positioned to benefit from this growth. We recently announced our expansion outside of Arizona, with a partnership in Kentucky, and we expect additional progress in our efforts to diversify our revenues internationally. This listing is an obvious next step in our global expansion.”

About Vapen MJ Ventures

Vapen MJ, through its wholly-owned subsidiaries, currently operates in the US as an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (THC and CBD cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of high margin Cannabis THC and Hemp CBD products under the Vapen Brand.  Vapen MJ expansion plans include partnering with cannabis license holders and hemp farms in multiple states within the US.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vapen MJ’ periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of Vapen MJ.

Although Vapen MJ has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; are engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vapen MJ disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vapen MJ does not assume any liability for disclosure relating to any other company mentioned herein.

SOURCE Vapen MJ Ventures Corporation

View original content: http://www.newswire.ca/en/releases/archive/June2019/14/c9310.html

Bob Brilon, President and CFO, T: 602-620-9725, Investors@VapenMJ.comCopyright CNW Group 2019

Published at Fri, 14 Jun 2019 13:11:52 +0000

Relevium Technologies Continues To Advance Its Fundamental Story In Both The THC and CBD Verticals

Relevium Technologies Continues To Advance Its Fundamental Story In Both The THC and CBD Verticals

Earlier this year, we issued an update on Relevium Technologies (RLV.V) (RLLVF) and believe that this is an opportunity to be following. The last month has been quite busy for the company and we are excited about the recent developments. Relevium represents a multi-faceted growth opportunity that is working to capitalize on some of the most attractive verticals of the cannabis industry.

One of the reasons we are excited about Relevium is due to its attractive operating structure and we believe that this enhances its overall growth prospects. Currently, the company operates through two wholly-owned subsidiaries which we have highlighted below:

  • BGX E-Health LLC (BGX): BGX markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix brand portfolio in the United States and Europe. Bioganix is currently being sold by some of the world’s largest retailers including Walmart.com and Amazon.com.
  • Biocannabix Health Corporation (BCX): BCX is focused on creating a vertically integrated medical cannabis company for the endo-medicinal products for pediatric care into the Canadian market.

Through a series of  growth initiatives, Relevium has been developing a premium line of products and we are favorable on the continued execution. The company’s strategy for developing and growing its brands includes expanding its product offerings, adding new distribution channels, and developing partnerships that add value through exclusive formulations.

Although Relevium has been able to significantly advance its fundamental story, the market has not responded accurately to the recent developments and we believe that this opportunity is flying under the radar. During the last month, the company has recorded some major milestones and we have provided an update on      the latest developments.

Reports a Significant Investment and Planned Acquisition

Last week, Biocannabix executed a letter of intent to acquire 30% of Weedsense Inc., a late stage applicant for standard processing and federal medical sales licenses. Weedsense is building a wholesale and distribution business in Montreal and will be working with licensed producers/processors and will be distributing directly to medical patients through a network of pharmacies and clinics. Weedsense also plans to service the recreational market by acting as a distributor to provincially-sanctioned wholesalers such as the Ontario Cannabis Store (OCS) or Société Québécoise du Cannabis (SQDC).

Weedsense can also act as a secured third-party logistics (3PL) partner for other market participants who seek direct access to the Quebec market for their products. Weedsense has applied for a standard processing and medical sales licenses through Health Canada and is constructing an EU GMP compliant facility in Montreal. Weedsense expects to be fully licensed by the fourth quarter of 2019 and obtain the EU GMP certification shortly after.

The investment into Weedsense provides Biocannabix with the capability to import, export, warehouse, package and sell directly to medical patients      and hospitals in a secure and compliant manner. Under the agreement, Biocannabix has the option to acquire 100% of Weedsense after the granting of the licenses by Health Canada. One of the reasons we are favorable on this transaction is because it is conditional on the granting of the licenses by Health Canada. This relationship will help Biocannabix in its mission to become a leader in providing safe, organically sourced endo-medicinal products for pediatric care int      the Canadian market. T     his could prove to be a major value driver to the entire business.

The idea behind Weedsense from the beginning has been to offer patients the best possible service as well as fairly priced premium products. We believe that the cannabis industry needs a patient centric wholesale/distribution platform and we will monitor how the team is able to execute on this.

Issues Update on its Cannabis and CBD Strategy

Earlier this month, Relevium released an update on its positioning and strategy regarding       medical cannabis and      CBD market opportunities     . This update came after the FDA held a public hearing on      its role in regulating cannabis-derived products such as CBD as nutritional supplements.

The FDA’s position is that although hemp is no longer an illegal substance under federal law, the FDA continues to regulate cannabis products under the Food, Drug, and Cosmetic Act (FD&C) and Section 351 of the Public Health Service Act. Therefore, and until their position changes, any cannabis product marketed with a claim of therapeutic benefit, regardless of whether it is hemp-derived, must be approved by the FDA before it can be sold. The statement also confirms that the addition of CBD to food products and dietary supplements is unlawful.

The public hearing was the first of many steps towards allowing CBD as a supplement, which would then allow companies like Relevium, who fall under the supplement jurisdiction of the FDA, to provide current and future customers with trusted nutraceutical formulations containing full-spectrum CBD through its LeefyLyfe and Bioganix brands across the US.

Under the FD&C Act, cosmetic products and ingredients are not subject to pre-market approval as long as the product does not make a health claim. This is important since the company is also testing skin care formulations under its Push and Pull brand formulated with CBD. This is something we are watching since the new skin care line is expected to serve as a major growth driver for the Bioganix family of products.

The European authorities in Europe and the UK have taken similar positions to the US by allowing the sale of full-spectrum hemp oil and hemp CBD as long as no medical claims are made. We have been bullish on the European CBD opportunity due to size of the population and the existing demand for these products.

In Germany, in order to be able to make a medical claim, companies have to register their products with the health authorities to obtain a PZN (Pharma-Zentral-Nummer), which is a national code for medicine identification across Germany. A PZN is needed for a company to make health claims and for the company’s products to be sold through pharmacies across the country. Through a strategic partnership with a German company, Relevium is working to have several formulations registered under a PZN and plans to market these products available through pharmacies and major health portals.

Relevium has also been aggressively pursuing South American opportunities. Initially, Biocannabix was focused on building out a facility in Canada but the high costs associated with this project, the company to pivot its strategy. Instead, Biocannabix is looking away from cultivation, at other segments of the industry with the Weedsense transaction, while securing and controlling plant genetics and extracts from South America. We are favorable on the economics associated with cultivation in South America and will monitor how the team is able to execute on this opportunity.

An Opportunity to be Watching

When looking at Relevium Technologies, we see an under-appreciated opportunity that has significant catalysts for growth. We believe that the recent pressure on the stock is waning and we see the tides potentially turning for Relevium Technologies.      The US symbol (OTCQB: RLLVF) recently received DTC edibility     .

During the last year, Relevium has reported several significant developments and has been generating much stronger revenues. This is an important trend and one that we will continue to monitor. We expect to see continued growth as the company’s products continue to gain traction and find this to be significant. The recent investments and acquisitions have significantly enhanced the company’s overall growth prospects, and this is an opportunity that we will continue to closely monitor.

If you are interested in staying up to date with Relevium Technologies, please contact support@technical420.com.

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Fri, 14 Jun 2019 10:05:28 +0000

Greenstar Announces Execution of Long Term Cannabis Flower Supply Agreement

Greenstar Announces Execution of Long Term Cannabis Flower Supply Agreement

Greenstar Biosciences Corp. (CSE: GSTR) is pleased to announce that its tenant partner in Washington State, Cowlitz County Cannabis Cultivation, Inc. , has signed a long-term supply agreement with Pat Dullanty, owner and operator of an 18 acre tier 3 outdoor grow facility located at 26425 S Rupp Rd, Cheney, Washington 99001. Pursuant to this new agreement, Cowlitz will have access to up to 25,000 pounds, dry weight, of high-quality flower annually. The facility has significant room for expansion in both land and available high-quality spring water and gives Cowlitz a strong and stable supply of cannabis flower for years to come. A video of the Dullanty facility is provided below:

https://youtu.be/lQ6MhlAZsjw

Greenstar is the owner of the property leases, brands and intellectual property of Cowlitz County Cannabis Cultivation Inc., a licensed cannabis producer and processor located in Washington State. Learn more about Greenstar at www.greenstarbiosciences.com.

Cowlitz is a leading producer, marketer and vendor in the Washington State recreational cannabis market. Known for sourcing high-quality cannabis sold at affordable prices to a broad and established consumer base, Cowlitz’s portfolio of branded products is available at approximately 20% of cannabis retailers throughout Washington State. Cowlitz brands include; Columbia Valley Private Reserve, Cowlitz Creeper, Cowlitz Gold, High Guys and Dab Dudes and they have seen steady growth in the past five years. Cowlitz exceeded $14M in revenue for the 2018 calendar year and is on pace to exceed that number again in 2019. A critical element of that success is the availability of, and the ability to source and procure quality raw material cannabis flower to feed their growing demand. This agreement helps ensure that Cowlitz will be able to meet that expected demand despite current shortages within the state and expected future supply fluctuations.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available.

For further information please contact:

Greenstar Biosciences Corp.
Ralph Olson, CEO
Tel: (303) 807-4827

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Transaction and the future plans and objectives of the Company, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the Transaction will be completed and that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

SOURCE: Greenstar Biosciences Corp.

View source version on accesswire.com:
https://www.accesswire.com/548517/Greenstar-Announces-Execution-of-Long-Term-Cannabis-Flower-Supply-Agreement

Published at Wed, 12 Jun 2019 12:03:22 +0000

Wildflower Demand Outpacing Production

Wildflower Demand Outpacing Production

Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF) (the “Company” or “Wildflower”) announces that new production facilities are in the process of being built to meet increasing demand.  Wildflower products can be found in over 300 stores nationwide in the U.S. and have recently been picked up by several national retail chains.

To meet this demand, Wildflower has added a second shift at its existing production facility. Even with this increase in production, capacity is at 90%. The new facility is critical to the company’s growth strategy.

New production equipment has been purchased and is on site to completely automate the production of multiple product lines. Completion of the new facility is expected in August 2019 and will have the effect of increasing our production capacity by more than 10-fold.

William MacLean, Chief Executive Officer of Wildflower, states, “We are excited to get our new production facility up and running in order to meet the demand. We receive inbound contact daily by new retailers and distributors reaching out to us to carry our products and with production at near capacity we need the expanded manufacturing.”

About Wildflower Brands

Wildflower Brands is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products. All of our brands work in synergy, toward becoming a global wellness leader.

FURTHER INFORMATION

The Canadian Securities Exchange Inc. has neither approved nor disapproved of the contents of this press release.

For more information about Wildflower Brands, visit wildflowerbrands.co. To learn, engage and shop our wellness products visit buywildflower.com.

Investor Relations Contact:

Will Elston, Investor Relations

ir@wildflowerbrands.co

1-604-559-0420

Corporate Communications:

NetworkWire (NW)

New York, New York

www.NetworkNewsWire.com

212.418.1217 Office

Editor@NetworkWire.com

Cautionary and Forward-Looking Statements

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. Forward‐looking statements and information are often, but not always, identified by the use of words such as “appear”, “seek”, “anticipate”, “plan”, “continue”, “estimate”, “approximate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “would” and similar expressions.

 Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with the marijuana industry in general such as operational risks in growing; competition; incorrect assessment of the value and potential benefits of various transactions; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and government regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement. The Canadian Securities Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release.

 

Pursuant to an agreement between StoneBridge Partners LLC and WildFlower Brands we have been hired for a period of 60 days beginning May 1, 2019 and ending July 1, 2019 to publicly disseminate information about (SUN) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (SUN) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (SUN), which we purchased in the open market. We plan to sell the “ZERO” shares of (SUN) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (SUN) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Share - Facebook


Share - Twitter

Authored By

mberger

Michael Berger is the Founder of Technical420 and Managing Partner of StoneBridge Partners. Prior to entering the cannabis industry, Michael worked as an Equity Research Analyst at Raymond James Financial and recognized a major information void when it comes to the cannabis industry while working in this position. Michael continues to be one of the top authorities on cannabis equities in the industry.

Published at Mon, 10 Jun 2019 16:04:36 +0000

Aphria adds to planned portfolio of vapes & concentrates with PAX Labs agreement

Aphria adds to planned portfolio of vapes & concentrates with PAX Labs agreement

Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA and NYSE: APHA) today announced an agreement with San Francisco-based PAX Labs, Inc. (“PAX“), a leader in the design and development of premium cannabis vaporization devices, that will enable Aphria to provide premium cannabis extracts in pods designed for use with PAX’s innovative Era device and platform. The Company plans to introduce PAX pods for both adult-use consumers and medical patients, pending anticipated changes to the Cannabis Act to permit the sale of cannabis extracts for vaporization.

Aphria Inc. (CNW Group/Aphria Inc.)

“As Aphria continues to drive the evolution of the industry, we are thrilled to partner with a technology leader like PAX to provide a new avenue for consumers to integrate cannabis into their lives,” said Irwin Simon, Interim CEO of Aphria. “We are excited to bring our premium cannabis extracts from Solei, RIFF and our flagship medical cannabis brand, Aphria, to the PAX Era device and platform.”

PAX has already sold more than 500,000 Era devices for oil concentrates in the United States and continues to see expansive growth.

“The expected legalization of vapes and concentrates will mark a significant turning point in the Canadian market, providing more choice and new experiences, while opening the door to a range of new consumers,” added Simon. “Our strategic alliance with PAX sets the stage for our broad portfolio of vapes and concentrate products to come.”

Aphria estimates Vapes & Concentrates will represent close to 30% of the entire Canadian adult-use market by 2021.

“This collaboration compliments Aphria’s growing roster of strategic innovation partners, including Manna Molecular Sciences and Rapid Dose Therapeutics, as we pursue new innovations that will change the way consumers interact with cannabis in the future,” said Simon.

We Have A Good Thing Growing

About Aphria Inc.
Aphria Inc. is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

For more information, visit: aphriainc.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to the future composition of the cannabis market. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability of Aphria Inc. to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks, including those set forth in our public filings on SEDAR and EDGAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/aphria-adds-to-planned-portfolio-of-vapes–concentrates-with-pax-labs-agreement-300863846.html

SOURCE Aphria Inc.

Published at Fri, 07 Jun 2019 13:39:28 +0000

Vapen MJ Ventures Brings CBD Extraction to Kentucky 8th Generation, Family Owned Farm

Vapen MJ Ventures Brings CBD Extraction to Kentucky 8th Generation, Family Owned Farm

Vapen MJ Ventures Corporation (CSE: VAPN) (“Vapen MJ”) a fully integrated agricultural technology, services and property management company in the regulated cannabis industry announced today that it is bringing its extraction expertise to a Kentucky partnership for CBD extraction.   First harvest and initial extraction production is anticipated in fall of 2019 and expected to generate approximately CAD$24 million in wholesale refined, high purity CBD oil in the first year of operation.

Vapen MJ and Emerald Point Hemp will form a new entity, Vapen-Kentucky LLC (“Vapen-Kentucky”).  Emerald Pointe Hemp is an eighth-generation family-owned, farming business, that has a proven record of growing hemp for many years.  Emerald Pointe Hemp has initially dedicated 100 acres of their 6,000-acre farm to the cultivation of hemp specifically dedicated to Vapen-Kentucky, for its extraction and wholesale distribution operations.  Vapen-Kentucky will process hemp for refined, high purity CBD oil, utilizing the industrial hemp grown by Emerald Pointe.  Vapen MJ and Emerald Pointe Hemp will share equally in the net profits generated from the CBD extraction and wholesale distribution business of Vapen-Kentucky.  All products produced through Vapen-Kentucky will bear the “Vapen” brand.

Thai Nguyen, chief executive officer of Vapen MJ commented that “Our multi-state expansion strategy includes partnering with cannabis license holders as well as hemp producers with our THC and CBD extraction expertise.  Through our relationship with Emerald Pointe Hemp, we will have direct control over raw materials for our Vapen CBD products and with that the unlimited capacity to expand our sales strategies for CBD domestically and internationally.”

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vapen MJ’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of Vapen MJ.

Although Vapen MJ has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; are engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vapen MJ disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vapen MJ does not assume any liability for disclosure relating to any other company mentioned herein.

SOURCE Vapen MJ Ventures Corporation

For further information: Bob Brilon, President and CFO, T: 602-620-9725, Investors@VapenMJ.com

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Wed, 05 Jun 2019 13:14:31 +0000

Relevium’s Biocannabix Executes LOI to Acquire 30% Interest in Weedsense, a Late Stage Applicant for Standard Processing and Medical Sales License

Relevium’s Biocannabix Executes LOI to Acquire 30% Interest in Weedsense, a Late Stage Applicant for Standard Processing and Medical Sales License

Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly owned subsidiary Biocannabix Health Corporation (“Biocannabix”) has executed an LOI to acquire 30% of Weedsense Inc., a late stage applicant for standard processing and medical sales license.

WEEDSENSE STRATEGIC FIT FOR BIOCANNABIX ENDO-MEDICINAL BUSINESS

Weedsense Inc. (“Weedsense”) is building a wholesale and distribution business in Montreal, Québec. The Company’s business model includes wholesale and bulk products from licensed producers or processors and distributing directly to medical patients through a network of pharmacists or clinics. Weedsense will also service the recreational market by acting as a distributor to provincially-sanctioned wholesalers such as the Ontario Cannabis Store (OCS) or Société Québécoise du Cannabis (SQDC).

Weedsense can also provide secured third-party logistics (3PL) partner for other market participants who seek direct access to the Quebec market. Weedsense has applied for Standard Processing and Medical Sales licenses through Health Canada and is building a euGMP facility in Montreal. The late stage applicant “Weedsense Inc.” expects to be fully licensed no later than Q4 2019 and obtain euGMP certification shortly thereafter.

Biocannabix Health Corporation will entrust Weedsense with the storage, sales and distribution of its endo-medical nutraceuticals and medical food products for the Canadian marketplace including pharmacies and hospitals. Biocannabix mission is to become a leader in providing safe, organically sourced endo-medicinal products for pediatric care into the Canadian market.

Aurelio Useche, CEO of  Relevium stated: “Our investment into Weedsense provides Biocannabix with the capability to import, export, warehouse, packaging and sell to pharmacies and hospitals in a secure and compliant manner. This is another milestone in our vertically integrated model for the Pediatrics market”

Dave Shepard, CEO and Co-Founder of Weedsense Inc. stated: “The idea behind Weedsense from the beginning has been to offer patients the best possible service: amazing products at a fair price, the best customer service possible and timely delivery. I have been successful building out this model already in the beauty space with beautysense.ca and it was clear that a patient centric wholesale/distribution platform was lacking in the cannabis market.”

Sasha Asgary, COO and Co-Founder of Weedsense Inc. stated: “We have had the luxury of building Weedsense after having observed market dynamics for the last two years. We are employing best in class cannabis consultants and engineering firms that have all won awards in their respective categories at industry events and guided us exceptionally well through our licensing process. There is no doubt in our minds that we are building a platform that will win the hearts of patients locally and nationally.”

TRANSACTION STRUCTURE

Biocannabix has executed an LOI to invest CAD$1.5 million into Weedsense Inc. to obtain an initial 30% interest in the company. In addition to its initial investment, Biocannabix has secured an additional option to acquire 100% of the shares after the grant of the licenses by Health Canada and full construction of the facility for an additional CAD$3.5 million payable in shares of Biocannabix at a valuation equals to that of the eventual series “A” financing of the wholly-owned subsidiary.

The transaction is conditional to the grant of the said licenses by Health Canada, financing and is also subject to the approval to the TSXV Stock Exchange.

About Relevium Technologies

Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Wed, 05 Jun 2019 14:04:18 +0000

Next Green Wave Provides Corporate Update

Next Green Wave Provides Corporate Update

Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) The CEO and Executive Chairman of NGW, Leigh Hughes is pleased to provide an update on the progress of The Company’s operations.

As a young public company, we continue to demonstrate the energy, drive and passion of a “start-up” that is influenced by our strong values and long-term vision. With the groundwork now in place, we anticipate 2019 to be a significant year as we begin to generate revenue, launch products, and continue to serve a larger role in the California premium cannabis space -both as an authorized producer and distributor of major brands and labels.

We are part of a fast-growing and highly competitive industry and need to stay ahead of the curve to provide customers with a superior experience and product. As such, we are continually evaluating our priorities and best practices to seize opportunities and overcome the challenges that arise in this new marketspace.

How do we build a resilient brand and product portfolio? How do we tune out the noise and prepare for the long term? We believe that having the systems in place to adopt and innovate quickly differentiate us from the rest and enable us to serve clients, inspire employees and deliver value to shareholders.

“Next Green Wave’s mission is to unlock the full potential of the cannabis plant, in ways that cater to all industries and individuals around the world.”

Over the next three years, Next Green Wave will strive to become a top tier cannabis brand in California through our infrastructure, acquisitions and the targets we have set in the premium recreational segment. In March we accelerated our value proposition through the acquisition of SD Cannabis (“SDC”) and will now direct our efforts to build out a world-class nursery in collaboration with Intrexon.

In this update, we share the highlights of our performance, our notable achievements since going public in October of 2018 and our aspirations for the year to come.

In closing, the Board remains diligent and is also confident it has the right business model and the right objectives for successful execution, drive growth and to create stakeholder value. With that, we have the opportunity to shape the future of our emerging industry and to unlock the full potential of the cannabis plant.

Commencement of Cannabis Production at Facility A

In late April, we began our breeding program to build up our nursery stock to populate our 14 grow rooms over the next couple months. When we reach our optimal production schedule, the garden crew will harvest two grow rooms every 10-14 days ensuring a constant supply to our vendors. The full cycle from seedling to sale is anticipated to take about four months. Revenue from the cultivation process is expected to take place in Q3.

In early April 2019, our HR department hosted a 2-day offsite on-boarding that focused on company alignment and culture building with the entire Facility A team and officials from the City of Coalinga. Their participation energized and encouraged the team to be not only valuable employees, but valuable members of the community at large.

In early May 2019, we implemented our automated Track and Trace Compliance System (“Trellis”). This involved the Trellis Executive Team to be on-site and oversee a successful on-boarding and implementation with our COO, VP Finance, Compliance Officer and Gardener’s.

We are on track for the full retrofit and activation of our 3,240 square foot Facility C in late Q2, which will be used for our non-volatile extraction activities. Facility C will also be used for research and development and we are excited about the prospect of working with other partners to bring new cultivars and product lines to the cannabis space through this facility. We have received all conditional use permits related to Facility C and submitted our application license for both volatile and non-volatile extraction activities with the State of California (California Department of Public Health) in Early May.

Our Vision to be Number 1 in Cannabis Consumer Product Goods in California

Next Green Wave is now focused on integrating SDC’s 8 brands, 45 THC and CBD products, extraction and manufacturing team while calibrating its recently completed 35,000 sq. ft Facility A. We have now integrated SDC’s extraction and manufacturing expertise into our facilities and are currently fitting out Facility C which will house the company’s extraction business.

In the coming months, our Brand Partners product lines will be introduced into the California and online direct-to-consumer market in the United States. With a combined social media reach of over 25 million across the globe, these Brand Partners include;

Carey Hart
View on Instagram ( 969k Followers )

Loki the Wolf Dog
View on Instagram ( 2 Million Followers )

King Louie
View on Instagram ( 383k Followers )

Sketchy Tank
View on Instagram ( 235k Followers )

Junkyard LA
View on Instagram ( 85.7k Followers )

Toy Machine Skateboard Co
View on Instagram ( 628k Followers )

SD Cannabis
View on Brand House Instagram

View Product on Instagram

NoJumper OSS
View NoJumper on Instagram (1.3 Million Followers )

View Adam 22 on Instagram ( 1.5 Million Followers )

Thorn St. Beer
View on Instagram ( 28.4k Followers )

In March, we successfully launched the Loki Naturals product range through its online store www.lokinaturals.com Our initial test run of Love Biscuits and Tinctures were sold by advertising across Loki’s social media platforms. The engagement and sales response was strong, and we are optimistic on the consumer acceptance of all 8 brand partners and 45 product lines all hitting the shelves and online platforms over the next few months.

Building a World-Class Nursery with Intrexon

The implementation of Intrexon’s next generation (non-GMO) tissue culture platform, Botticelli™ began in Q1 and as part of the first phase of the project, the companies will calibrate this technology specifically to Next Green Wave’s cannabis cultivars toward rapid and sustainable cannabis plantlet production.

The Botticelli™ platform is an advanced tissue culture technology designed to enable efficient propagation of plants while maintaining genetic purity and product performance. When applied to cannabis, Botticelli™ offers potential for a sustainable, scalable, and more economical solution than conventional clones.

Cannot view this image? Visit: https://medicalmarijuanadelivery.biz/wp-content/uploads/2019/06/IGCQJg.jpg



Intrexon

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6127/45194_e0163bfe24545aa6_001full.jpg

The objective of this optimization phase will be to demonstrate that Botticelli™ will allow for cost effective cannabis plantlet production compared to the traditional cloning applications in today’s market.

This will offer the cannabis market several advantages:

• Rapid multiplication of proprietary lines in smaller areas;

•Reduction or potential elimination of mother rooms;

• Substantially decreased cutting load on the mother plants ensuring genetic purity and product performance;

• Reduced phytosanitary risk and superior product performance;

• A more integrated production system and shorter time to vegetation room; ex., reduction or elimination for vegetative acclimatization step; and

• Capital efficiencies.

In 2019, Next Green Wave and Intrexon will work together to achieve the following key project deliverables:

  • Quarter 1: Utilize Next Green Wave’s hemp CBD strains as a proxy to optimize standard operating procedure at Intrexon’s Davis, California facility.
  • Quarter 2: Intrexon to complete tissue culture lab build out at Next Green Wave’s 3,240 sq. ft Facility “Site C”.
  • Quarter 3: Intrexon becomes operational at Next Green Wave’s 3,240 sq. ft Facility “Site C”. Tissue culture lab ready and operational.
  • Quarter 4: Optimization of Botticelli™ SOP to 10 Next Green Wave THC cultivars ready for scale-up production and commercialization in 2020.

International Expansion Through Brand Licensing Opportunities

As the global cannabis landscape continues expand in 2019, Next Green Wave will take advantage of specific international markets that will allow our brands and products to be licensed through other respectable international partners. Our investment and strategic partnership with Organic Medical Growth (“OMG”) which will see our distribution channel expand by over 7,000 pharmacies in Colombia through a brand licensing agreement with OMG.

Cannot view this image? Visit: https://medicalmarijuanadelivery.biz/wp-content/uploads/2019/06/hVXWOD.jpg


OMG
To view an enhanced version of this graphic, please visit:
https://medicalmarijuanadelivery.biz/wp-content/uploads/2019/06/hVXWOD.jpg

To ensure that OMG goes to market with a premium product, we will be providing expertise and services to ensure that OMG’s nursery, cultivation and extraction techniques are of the highest standard. These services have begun, and we expect that in 2019, a range of our brands will be selling into Colombia and on a path to generating revenues. In May, we recently did our first site visit to OMG’s facilities.

OMG is expecting to go public in Canada in late 2019 with Next Green Wave having a 10% equity ownership post its first initial public offering financing round and the option to purchase up to another 5% of the company post its first initial public offering financing round.

Financed to Accelerate Rapid Growth

This week we announced a close on a $6M convertible note offering which provides two $3M tranches. The 2nd tranche will be delivered at the sole discretion of Next Green Wave without any obligation to give the financial flexibility to execute our growth strategy while continuing to maintain and protect shareholder value. Proceeds of the Offering will be used for the acceleration and rollout of Next Green Waves’ brands and products throughout California in 2019.

Shareholder Value through Revenue

Now that we have become a licensed cannabis producer in California and commenced the integration of the SD Cannabis acquisition (“SDC”), we anticipate strong output, and more importantly, synergies from our Cultivation Facility (“Site A”) and our Extraction Facility (“Site C”).

The monthly output is expected to be 650 to 750 lb’s per month of premium flower from Facility A and 110 to 120 kg’s per month of extracted oil from Facility C.

Our SDC brand partnerships and products are expected to sell approximately 30,000 units per month with full market activation in 2019.

Next Green Wave’s Rejuvenated Brand & New Website Launch

We recently announced the launch of our rejuvenated company brand and visual identity. With a focus on innovative and open lines of communication with our stakeholders, we have also launched an entirely new website that provides a far more in-depth look at our brand portfolio, facilities, partners and our overall business. www.nextgreenwave.com

With a desire to elevate life’s moments for our industry, stakeholders and consumers, we are looking beyond just the product to create a more personal lifestyle connection with our communities. You can also catch the action in real time through our Twitter, Facebook and Instagram accounts@nextgreenwave.

The Opportunity Ahead in 2019

Next Green Wave continues to remain focused to ensure that we meet our key milestones and expectations of all stakeholders in 2019. In line with our strategic plan, in 2019 we will also be focused on delivering in the following key areas;

• Activating our nursery business to develop world-class hybrid cannabis strains for direct retail and wholesale;

• Achieving full operation capabilities of our flagship 35,000 sq. ft Facility “Site A”;

• Activation of our extraction facility in late Q2 to begin producing oils, tinctures, and extracts for custom vaporizer products;

• Securing our distribution network into California through our SD Cannabis brand acquisition and the roll out of 8 more brands and 43 products with influential branding partners;

• Obtaining access into international markets through investments in licensed cultivators and distributors such as OMG;

• Establishing research and innovation amenities and procedures for continued product and branding development.

The Company also wishes to announce that David Wilson has resigned as a Director of the Company. The Company thanks Mr. Wilson for his dedication and commitment and wishes him well in his future endeavours.

About Next Green Wave

Next Green Wave is a vertically integrated seed-to-consumer premium medicinal and recreational cannabis company operating in California. The Company’s first state-of-the-art indoor facility (35,000 ft.2) is now entering production with future plans to expand the 15 acres of cannabis zoned land it is situated on. NGW has acquired a seed library of over 120 strains which include several award-winning genetics and cultivars. Recent acquisition of SDC Ventures will complement NGW’s branded products and accelerate the company to revenue through SDC’ existing partnerships and labels. The investment in OMG will provide NGW access to distribution through the licensing of our brands through Colombia. To find out more visit us at www.nextgreenwave.com or follow us on Twitter at @nextgreenwave, on Instagram, and LinkedIn.

On behalf of the board,

Leigh Hughes,
CEO and Executive Chairman
Next Green Wave Holdings Inc.

Next Green Wave Forward Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the risk factors included in the preliminary prospectus, including without limitation dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete construction of its proposed facilities in a timely manner; engaging in activities which currently are illegal under US federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; NGW’s limited operating history and lack of historical profits; reliance on management; NGW’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of Tranche 1 and Tranche 2 of the Notes; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. Readers are encouraged to the review the section titled “Risk Factors” in NGW’s prospectus. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although NGW has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. NGW no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

For more information regarding Next Green Wave, contact:
Caroline Klukowski
VP Corp. Development
Tel: +1 (778) 589-2848
IR@nextgreenwave.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/45194

copyright (c) newsfile corp. 2019

Published at Fri, 31 May 2019 14:07:15 +0000

CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019

CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019

CB2 Insights (CSE:CBII; OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the first quarter of 2019. Additional information concerning the Company, including its unaudited financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended March 31, 2019, can be found at www.sedar.com and on the Company’s website. All amounts are expressed in Canadian dollars unless otherwise noted.

Q12019 Financial Highlights

  • Revenue for the quarter was $2.9 million, a 16.4% increase over the previous quarter and based solely on organic growth within the Company’s Canna Care Docs brand;
  • Revenue contribution from its newly acquired MedEval and Relaxed Clarity clinic groups would have been an estimated $500 thousand for the quarter, which would have boosted revenue to $3.4 million for the quarter and increased the Company’s revenue growth rate to over 37% quarter-over-quarter;
  • Gross profit of $2.2 million for the quarter, or gross margin of 77% represents an increase from 70% from the prior quarter;
  • Operating expenses for the quarter were reduced by more than $785 thousand from the prior quarter as a result of management’s operational efficiency analysis;
  • At quarter end the Company had cash of $1.6 million on hand compared to $433 thousand from the prior quarter; and
  • Adjusted EBITDA1 loss of $713 thousand in Q1 2019 versus Adjusted EBITDA loss of $1.81 million in Q4 2018*.

*Note: Q1 2019 Adjusted EBITDA1 from US clinical operations (not inclusive of any subsequent-to-quarter-end acquisitions) resulted in a gain of $578 thousand. CB2 currently uses this surplus in cash flow to fuel its Data and Analytics business, which includes but is not limited to software development, product development, analytical and commercialization teams.

“CB2 saw a strong organic growth in our top line paired with a substantial reduction in our operating expenses in the quarter. This growth did not include contributions from our new, profitable clinical acquisitions of MedEval and Relaxed Clarity,” said Prad Sekar, CEO, CB2 Insights. “We remain committed to growing our clinical business, reducing our burn rate and working towards commercializing our RWE / data asset. We have made significant progress in each of these areas over the past quarter and are confident that our valuation should begin to reflect this. Over the past several months, we have had meaningful conversations with many large-scale traditional Life Sciences stakeholders and are working towards commercialization of our data assets to help usher in a new level of understanding regarding cannabinoid therapy across the traditional healthcare sector. As we look to continue acquiring additional clinical groups in the coming quarters, we are excited to have received validation by major industry players that the path that we are on holds significant prospective value to those both inside and even more so, outside the medical cannabis industry.”

Q1 2019 Operational and Strategic Highlights

Operational and Strategic Highlights Subsequent to Quarter End

CB2 Insights’ Divisional Highlights

CB2 Insights operates 3 primary divisions in the generation of health outcome data. These divisions are:

Clinical Operations: CB2 currently operates the largest network of physician-staffed medical centers in the US specializing in qualifying and supporting patients who are treating their indications with medical cannabis.

  • Added 4 new clinic locations within the quarter under Canna Care Docs brand;
  • Subsequent to quarter-end, successfully acquired Colorado-based Relaxed Clarity; and
  • Subsequent to year-end, successfully acquired Colorado and Arizona-based MedEval Clinics LLC.

Technology: CB2 has developed and deployed its proprietary cannabis-specific Electronic Health Record (EHR) technology platform to standardize the patient and clinical workflows within its clinics ensuring valid and structured anonymized and aggregate data collection protocols to support Real-World Data collection.

  • Successful integration of proprietary Sail EHR platform into Relaxed Clarity and MedEval Clinics LLC; and
  • Began integration with large EMR platform, Premier Health Group to provide access of CDS tool to nearly 5,000 physicians.

Data Insights: Applies analytical, machine learning and artificial intelligence (AI) technologies to the data the Company generates to derive insights that support stakeholders within the Life Sciences industry including drug manufacturers, patients, doctors/HCPs, regulators and payors.

  • Artificial Intelligence expert, Dr. Randy Goebel joins CB2 Insights as Sr. Advisor to Data Insights Division; and
  • Company engaged in successful exploratory sessions with international regulatory bodies, pharmaceutical companies and insurance firms to discuss Real World Evidence support for issues related to cannabis-based drug development, regulatory frameworks and drug spend.
    Quarter ended March 31, 2019   Quarter ended December 31, 2018
  Revenue   $2,849,811   $2,449,020
  Cost of sales   $655,688   $747,496
  Gross Profit   $2,194,123   $1,701,524
  Gross Margin   76.9%   69.5%
  Adjusted EBITDA1   $(712,582)   $(1,811,463)
  Net Income (Loss)   $(2,161,546)   $(2,539,776)
  Basic and diluted net loss per share   $(0.031)   $(0.0452)

CB2 is also announcing that it has completed a rights offering which was previously announced on February 27, 2019. Under the terms of the rights offering, CB2 issued a total of 7,281 common shares at a price of $0.45 per share for aggregate gross proceeds of $3,276.45.

The rights were issued to holders of record on February 15, 2019, prior to the completion of the Company’s reverse take over transaction with MVC Technologies Inc. No stand-by commitment or additional subscription privilege had been agreed and no commission was payable in connection with the rights offering. All unexercised rights are now null and void.

Following the completion of the rights offering, CB2 will have a total of 78,778,036 common shares issued and outstanding.

The net proceeds of the offering will be used for general working capital.

Earnings Conference Call

CB2 Insights’ management team will hold a conference call to discuss our 2019 Q1 Earnings on May 31, 2019 at 9:00am EDT (details below).

  Date:   Friday, May 31, 2019
  Time:   9:00 a.m. (EDT)
  US/Canada Toll Free Dial In:   1-800-319-4610
  Toronto Local Dial In:   1-416-915-3239
  International Dial In:   1-604-638-5340
  Call Name:   CB2 Insights Earnings Call

An archived replay of the conference call will be available on the Company’s website within 24 hours following the conclusion of the call.

Non-GAAP Financial Measures

This Press Release contains references to Adjusted EBITDA and Gross Margin. These financial measures are not measures that have any standardized meaning prescribed by IFRS and are therefore referred to as non-GAAP measures. The non-GAAP measures used by the corporation may not be comparable to similar measures used by other companies. Adjusted EBITDA is defined as “income (loss) before interest expenses, taxes, expenses related to listing on the Canadian Securities Exchange, depreciation, foreign exchange and financial expenses.

The Company uses these non-GAAP measures because they provide additional information on the performance of its commercial operations. Such tools are frequently used in the business world to analyze and compare the performance of businesses; however, the Company’s definition of these metrics may differ from those of other businesses. CB2 Insights will, at times, use certain non-GAAP financial measures to provide readers with additional information in order to assist investors in understanding our financial and operating performance. CB2 Insights believes that these non-GAAP measures provide readers with useful information about the Company’s operating results, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

Adjusted EBITDA excludes the effect of share-based compensation expenses and related payroll taxes as well as removes substantial one-time costs for unusual business activities. Within the 2018 reporting period, one-time costs associated with fees pertaining to the Company’s public listing are excluded from this figure. Additional discussion on this can be found in CB2 Insights’ Management Discussion and Analysis filed on SEDAR.

Such non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, the corresponding measures calculated in accordance with IFRS. See the Company’s audited Financial Statements for a reconciliation of the non-GAAP measures.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.

For more information please visit www.cb2insights.com.

Primary Contact:
Dan Thompson
Chief Marketing Officer
1.416.670.9316
dan.thompson@cb2insights.com

For Investor Inquiries:
Sean Peasgood
+1.647.362.8286
investors@cb2insights.com

For Media Inquiries:
KCSA Strategic Communications
cb2@kcsa.com

Forward-Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein. 

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Primary Logo

Published at Thu, 30 May 2019 20:22:01 +0000

Chemesis International Inc. Reports Fiscal Q3 2019 Financial Statements

Chemesis International Inc. Reports Fiscal Q3 2019 Financial Statements

Chemesis International Inc. (CSE: CSI) (OTC: CADMF), announces unaudited fiscal Q3 Financial Statements for the three months ending March 31, 2019. In this quarter;

  • the Company reported Revenue of $3,762,139, a 33% increase over the previous quarter, with Gross Profit of $1,113,903.
  • the Company closed the acquisition of La Finca Interacviva-Arachna Inc. SAS, an integrated cannabis company operating in Colombia with access to over 1,060 acres of outdoor cultivation.
  • the Company entered into a definitive agreement to manufacture a Proprietary Patent Pending THC Flake.
  • the Company announced an exclusive partnership with First Medical Cannabis bringing immediate access to 1,000 acres of hemp cultivation in Puerto Rico. Additionally, the Company has the option to expand to an additional 5,000 acres.

SUBSEQUENT EVENTS

  • the Company announced the closing of CDN $1,975,000 in equity financings.
  • the Company completed a definitive agreement for Acquisition of an extraction & manufacturing facility in Cathedral City. The acquisition expanded the Company’s processing ability to over 500,000 kg of cannabis annually.
  • the Company announced multi-state expansion into the Central United States, with teams concentrating on establishing operations in Michigan, Wisconsin, Missouri, and Illinois.
  • the Company announced it has received approval for three new cultivation licenses in Colombia, with the ability to expand to over 100 acres. Additionally, through its non-profit organization, Chemesis believes it will extend its sowing prospects to add an additional 10,000 acres within the next three years.
  • the Company announced it agreed with the holders of a $5.5 million promissory notes issued in connection with the Company’s acquisition of La Finca Interacviva-Arachna Med SAS to settle the full amount by issuing 4,104,476 common shares subject to 24 month leak out and escrow agreement.

Edgar Montero, CEO of Chemesis stated, “the Company’s operations continue to see increases in revenue quarter over quarter and we anticipate our operations will continue to grow as we see significant demand for the products we manufacture and package. The company’s revenues, accounts receivables, and inventory is as strong as ever. Chemesis is also putting forth further resources to expand into the Eastern United States to continue to expand the Company’s multi-state operations. The team has created a foundation that we believe will create significant opportunities in 2019.”

Chemesis international still has access to $32,625,000 in drawdown equity facilities between New York based Alumina Partners Inc and Global Emerging Markets at the company’s discretion.

The unaudited condensed consolidated interim financial Statements and MD&A for the three months ended March 31, 2019 will be filed on SEDAR and available at www.sedar.com.

On Behalf of The Board of Directors
Edgar Montero
CEO and Director

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico, and Colombia.

The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities. The Company operates a portfolio of brands which cater to a wide community of cannabis consumers, with focus on quality and consistency.

Chemesis has facilities in both Puerto Rico and California, and is in the process of constructing a GMP certified facility in Colombia. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft2 of cultivation, and 35,000 ft2 of manufacturing floor space. The Company is positioned to win additional licenses in highly competitive merit-based US states, and will expand its footprint to ensure it maintains a first mover advantage.

Investor Relations:
ir@chemesis.com
1 (604) 398-3378

Social Media:

Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
CaliforniaSap.instagram
Jay&SB.instagram

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing, including finalizing an acquisition in Colombia. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Primary Logo

Published at Fri, 31 May 2019 00:37:07 +0000